Moderna Is Getting $590 Million From the U.S. to Accelerate a Bird Flu Vaccine
The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.
Moderna Receives $590M From HHS to Develop Bird Flu Vaccine
This funding, announced Friday by Moderna, builds on the $176 million it received from HHS last year to support earlier stages of vaccine research.
Moderna awarded $590M to help accelerate development of mRNA-based bird flu vaccine: HHS
Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, health officials said.
US awards Moderna $590 million for bird flu vaccine development
Jan 17 (Reuters) - The U.S. government has awarded Moderna (MRNA.O), opens new tab $590 million to advance the development of its bird flu vaccine, as the country doubles down on efforts to tackle ...
U.S. Awards $590 Mln To Moderna For MRNA Pandemic Influenza Vaccine Development
The U.S. Department of Health and Human Services or HHS said it will provide approximately $590 million to Moderna (MRNA) to
Moderna Gets $590 Million of Federal Funding For Influenza Vaccines
The package will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines, the company said
US Health Dept Providing Moderna $590 Mn To Speed MRNA Bird Flu Vaccine
US health officials announced Friday they were awarding $590 million to Moderna to develop mRNA vaccines against influenza, including advancing the company's bird flu vaccine, as fears of a new pandemic grow.
Where Will Moderna Be in 3 Years?
Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...
Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares tumble
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
From Covid to Norovirus: Moderna’s mRNA Tech Takes on Stomach Flu
The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...
Piper Sandler Sticks to Its Buy Rating for Moderna (MRNA)
In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Moderna (MRNA – Research Report), with a price target ...
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Brooklyn Investment Group
Brooklyn Investment Group reduced its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 34.8% during the 4th quarter, ...
Despite Setbacks, Moderna Sees Opportunity In Avian Flu, Merck Partnership
Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.
Hold Rating on Moderna Amid Uncertain Near-Term Revenue from Pandemic Influenza Vaccine Efforts
In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Hold rating on Moderna (MRNA – Research Report), with a price ...